The purpose of this study is to investigate the feasibility of using ctDNA to support cancer diagnosis and risk stratification where invasive aerosol generating testing (and/or tissue biopsy) is challenging due to infection risk, technical impracticalities and resource limitations, such as during the COVID-19 pandemic and the subsequent recovery period.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
ctDNA detection rate within different cancer types (and overall)
Timeframe: Throughout study completion, up to one year
PREVAIL ctDNA Part 2 Study
Timeframe: To run parallel for 12 months alongside the ACCESS implementation programme